Goldman Sachs Group Inc Oncocyte Corp Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.25 - $15.6 $79,996 - $4.99 Million	-319,984 Reduced 83.87%	61,548 $19,000
Q4 2022 Feb 13, 2023	SELL	$0.25 - $15.6 $79,996 - $4.99 Million	-319,984 Reduced 83.87%	61,548 $19,000
Q3 2022 May 14, 2024	SELL	$0.76 - $15.98 $121,942 - $2.56 Million	-160,451 Reduced 29.6%	381,532 $279,000
Q3 2022 Nov 10, 2022	SELL	$0.76 - $15.98 $121,942 - $2.56 Million	-160,451 Reduced 29.6%	381,532 $0
Q2 2022 May 14, 2024	BUY	$0.86 - $1.53 $466,105 - $829,233	541,983 New	541,983 $487,000
Q2 2022 Aug 15, 2022	BUY	$0.86 - $1.53 $70,501 - $125,427	81,979 Added 17.82%	541,983 $487,000
Q1 2022 May 16, 2022	BUY	$1.15 - $2.25 $28,708 - $56,169	24,964 Added 5.74%	460,004 $686,000
Q4 2021 Feb 14, 2022	BUY	$2.04 - $3.59 $35,751 - $62,914	17,525 Added 4.2%	435,040 $944,000
Q3 2021 Nov 10, 2021	BUY	$3.53 - $5.89 $1.47 Million - $2.46 Million	417,515 New	417,515 $1.49 Million

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $294M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.